Patent Application
20170304286
The present invention related to a new indication of Paroxetine pharmaceutical composition, especially related to inhibition effect of Paroxetine pharmaceutical composition on a variety of cancer cells.
Cancer is the most popular disease cause of death in the world. The cancer patients are gradually increase yearly, therefore the treatment method of the cancer has become an important issue. The medical treatments of cancer can be classified as surgical treatment, radiation therapy, chemotherapy and target therapy. Generally, the cancer drug, whether chemotherapy drug or target therapy drug, is to inhibit cancer cells duplication and split to prevent the tumor growth and metastasis.
Recently, the drug design for cancer is mainly focused on development of high-specific drug molecules or target-based antibody. Averagely, only about five of 10,000 new drugs can successfully enter the phase I of clinical trials.
Otherwise, the manufacturing of the drug is also a big problem. When the drug starting the clinical trials, there are lots of problems need to overcome, such as drug safety, patient selection, trial dose and other issues. Even the drug has approved by the FDA and sales on the market, there still possibly face the situation of the poor drug response in patients. Furthermore, if the cancer patients happen the drug resistance, that would reduce the effectiveness of the drugs and result in the medical treatment failure. Therefore, the new drug development is very difficult.
Paroxetine, also known by the trade names Paxil and Seroxat, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive-compulsive disorder, social anxiety disorder, panic disorder, posttraumatic stress disorder, generalized anxiety disorder and premenstrual dysphoric disorder. Paroxetine is approved by FDA and accumulated a huge data of drug use and drug mechanism research.
Due to the differences of the clinical use, there is no research present that the paroxetine has any potential to inhibit cancer cell.
In order to solve the above problems, the present invention provide the development of new cancer clinical indications of Paroxetine.
Accordingly, the present invention provides a new indication of Paroxetine. The experimental results showed that the Paroxetine had no toxicity or had little toxicity to normal cells in the present invention.
The present invention provides a pharmaceutical composition of Paroxetine for treating cancer. The pharmaceutical composition is composed of effective dose of Paroxetine and a pharmaceutical acceptable salt.
In one embodiment of the present invention, the cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer.
In one embodiment of the present invention, the cancer is selected from osteosarcoma, skin cancer and blood cancer.
In one embodiment of the present invention, the pleural-related cancer is lung cancer.
In one embodiment of the present invention, the abdominal-related cancer is selected from bladder cancer, cervical cancer and kidney cancer.
In one embodiment of the present invention, the endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer.
In one embodiment of the present invention, the gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.
In one embodiment of the present invention, the effective dose of Paroxetine is from 20 mg/kg/day to 500 mg/kg/day.
Cell Culture
Subculture the different types of cancer cells. The cancer cells includes lung cancer, gastric cancer, hepatic cancer, colon cancer, skin cancer, cervical cancer, prostate cancer, bladder cancer, breast cancer, leukemia, pancreatic cancer, ovarian cancer, tongue cancer, osteosarcoma, and renal cancer. The normal cells used in the control group included kidney cells (HEK293), canine fibroblast cell line HFW, and human bronchial epithelial cell line BEAS-2B. (as shown in Table 1).
Cancer cell lines were cultured in different culture medium according to different characteristics (as shown in Table 1). The cell numbers were counted and reseed as 2×106 in culture plate/flask. Then, the culture medium were added to a volume of 10 ml, and the cells were cultured for 2-3 days. Then, the cells were suspended for loading into 96-well plates. The number of cells was 3000 and the volume of the culture medium was 100 μl each well.
Cell Viability Analysis
Removing the original culture medium from 96-well plate. Then add 100 μl of commercially drug at a concentration of 10 μM per well. After 72 hours, add the diluted WST-1 reagent to the well with 100 μl/well, and the diluted WST-1 reagent was acquired from the dilution of 9:1 medium and WST-1 stock reagent. Finally, the total volume of each well was 200 μl/well. Culture the 96-well plate at 37° C. for 30 to 90 minutes. Detecting and calculate the survival rate of each cancer cells with an ELISA reader at OD450 nm. The lower viability of cancer cells represents better inhibition effect via the Paroxetine drug. Otherwise, the higher viability of cancer cells represents worse inhibition effect via the Paroxetine drug.
The Effect of Paroxetine on Different Cancer Cell Lines
The Inhibition Effect of Paroxetine on Pleural-Related Cancer Cells
This inhibition test of Paroxetine on pleural-related cancer cells were using two lung cancer cell lines A549 and H1650. The inhibitory tests of Paroxetine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 2.
The Inhibition Effect of Paroxetine on Abdominal-Related Cancer Cell Lines
This inhibition test of Paroxetine on abdominal-related cancer cells were using bladder cancer cell lines TSGH and T24 (Table 3), cervical cancer cell lines HeLa and C-33A (Table 4), renal cancer cell line 786-O (Table 5).The inhibitory tests of Paroxetine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 3, Table 4, and Table 5.
The Inhibition Effect of Paroxetine on Endocrine-Related Cancer Cell Lines
This inhibition test of Paroxetine on endocrine-related cancer cells were using prostate cancer cell lines PC-3 and LNCap (Table 6), breast cancer cell lines MCF7 and MDA-MB-231 (Table 7),and ovarian cancer cell linesNIH-OVCAR-3 and TOV-21G(Table 8). The inhibitory tests of Paroxetine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 6, Table 7, and Table 8.
The Inhibition Effect of Paroxetine on Gastrointestinal Tract-Related Cancer Cell Lines
This inhibition test of Paroxetine on gastrointestinal tract-related cancer cells were using gastric cancer cell lines AGS and MKN-45 (Table 9), hepatic cancer cell lines HepG2 and Hep3B (Table 10), colorectal cancer cell lines HCT116-wt and LoVo (Table 11), pancreatic cancer cell lines AsPC-1 and BxPC-3 (Table 12), and tongue cancer cell line SAS (Table 13).The inhibitory tests of Paroxetine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 9, Table 10, Table 11, Table 12and Table 13.
The Inhibition Effect of Paroxetine on Other Cancer Cell Lines
This inhibition test of Paroxetine on other cancer cells were using osteosarcoma cell line U2OS (Table 14), skin cancer cell lines A375 and BCC (Table 15). The inhibitory tests of Paroxetine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 14 and Table 15.
The Experiment Design on Control Group
The Inhibition Effect of Paroxetine on Normal Cells
This inhibition test of Paroxetine on normal cells were using normal kidney cell line HEK293 (Table 16) and normal pulmonary epithelial cell lines BEAS-2B (Table 17). The inhibitory tests of Paroxetine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 16 and Table 17.
This inhibition test results of Paroxetine on all kinds of cells were shown in Table 18. It is clear that Paroxetine has a significant inhibitory effect on several cancer cell lines. As a result in the experiments of the present invention, Paroxetine has a significant inhibitory effect on various cancer cells. (
Animal Model Test of Gastric Cancer with Dose 100 mg/kg/day and 200 mg/kg/day
In this invention, the female mice were (BALB/cAnN.Cg-Foxn1nu/CrlNarl) purchased from National Laboratory Animal Center (Taiwan). The weight of the mice were 21±1 g. These mice were subcutaneously injected with gastric cancer cells (AGS) and then put these mice into different cage sat random. The drug test experiment was divided into three groups, include “control group”, “low dose group (100 mg/kg/day)”, and “high dose group (200 mg/kg/day)”. These mice were then injected test drug intraperitoneally once daily until the tumor size reached 100 mm3. The tumor sizes and body weight were measured twice a week. The tumor sizes were measured and calculated by formula: (L×W2)/2. L represents the tumor longest length. W represents the tumor shortest diameter. The experiment results were shown in Table 19.
According to the results in
According to the results in
Although the present invention has been described in terms of specific exemplary embodiments and examples, it will be appreciated that the embodiments disclosed herein are for illustrative purposes only and various modifications and alterations might be made by those skilled in the art without departing from the spirit and scope of the invention as set forth in the following claims.
This is a National Phase Application filed under 35 U.S.C. 371 as a national stage of PCT/CN2015/092780 filed Oct. 23, 2015, an application claiming the benefit under 35 USC 119(e) to the following U.S. Provisional Applications No. 62/068,298 filed Oct. 24, 2014, the content of each of which is hereby incorporated by reference in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2015/092780 | 10/23/2015 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62068298 | Oct 2014 | US |
